Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP150079)
National Cancer Institute (R01HG005859)
National Cancer Institute (P30CA016677)
Received: 13 January 2017
Accepted: 6 December 2017
First Online: 4 January 2018
Ethics approval and consent to participate
: The malignant and normal samples were acquired from early-stage (stages I-III) NSCLC patients evaluated at The University of Texas MD Anderson Cancer Center. The study was approved by the MD Anderson Cancer Center institutional review board (IRB) and all participants provided written informed consents.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.